NSCLC that has gotten worse during or after treatment with platinum-based chemotherapy.
Patients must have at least one tumor that can be evaluated by the doctor during the
investigational drug treatment. Any side-effects from prior chemotherapy must have
subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney
Exclusion Criteria: Any of the following will exclude patients from study participation:
receipt of more than 1 prior regimen of chemotherapy for NSCLC (repeat of the same
chemotherapy at different points in time count as 1 regimen). Irradiation to 25% or more of
bone marrow, prior high dose chemotherapy with bone marrow or stem cell support, current
participation in other clinical trials, pregnant or breast-feeding women, known
HIV-positive or AIDS-related illness.
further examination by the investigator is necessary.